Home LiteratureArticle Details
PMID: 16537700 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women.

dos Santos Silva I, Johnson N, De Stavola B, Torres-Mejía G, Fletcher O, Allen DS, Allen NE, Key TJ, Fentiman IS, Holly JM, Peto J

Abstract

High levels of circulating insulin-like growth factor-I (IGF-I) and its major binding protein (IGFBP-3) at premenopausal ages have been associated with an increased breast cancer risk. We conducted a cross-sectional study (215 premenopausal women and 241 after natural menopause) nested within the Guernsey prospective studies to examine the relationship between the IGF system and mammographic features of the breast. The mammographically dense area in the breast increased with increasing serum levels of IGF-I (P for linear trend, P(t) = 0.05), IGF-II (P(t) = 0.08), and IGFBP-3 (P(t) = 0.01) only in premenopausal women. IGF-II and IGFBP-3 serum levels were associated with increases in the mammographically lucent area in both premenopausal (P(t) = 0.01 and 0.04, respectively) and postmenopausal women (P(t) < 0.001 for both), but these associations were no longer statistically significant after adjustment for body mass index and waist circumference. Neither the IGF-I/IGFBP-3 nor the IGF-II/IGFBP-3 molar ratio was associated with any of these mammographic features. The number of A alleles at a polymorphic locus in the promoter region of the IGFBP-3 gene was associated with increasing mean IGFBP-3 levels in both premenopausal (P(t) = 0.01) and postmenopausal (P(t) <0.001) women but not with mammographically dense area. These results support the hypothesis that the IGF system may affect the amount of mammographically dense tissue in premenopausal women, possibly by promoting cell proliferation and inhibiting apoptosis in the fibroglandular tissue. The findings also show strong relations between IGF-II and IGFBP-3 levels and the amount of mammographically lucent tissue, reflecting the associations between body adiposity and amount of fat tissue in the breast and between body adiposity and circulating levels of these growth factors.

MeSH Terms
Adult Age Distribution Base Sequence Biomarkers, Tumor/blood Breast/metabolism,pathology Breast Neoplasms/diagnostic imaging,epidemiology,genetics Cross-Sectional Studies DNA, Neoplasm Enzyme-Linked Immunosorbent Assay Female Humans Incidence Insulin-Like Growth Factor Binding Protein 3/blood,genetics Insulin-Like Growth Factor I/metabolism Mammography Middle Aged Molecular Sequence Data Polymorphism, Genetic Postmenopause Premenopause Probability Prognosis Prospective Studies Reverse Transcriptase Polymerase Chain Reaction Risk Assessment Sensitivity and Specificity Sex Distribution
Chemicals
Biomarkers, Tumor DNA, Neoplasm Insulin-Like Growth Factor Binding Protein 3 Insulin-Like Growth Factor I
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
dos Santos Silva Isabel
Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom. isabel.silva@lshtm.ac.uk
Johnson Nichola
De Stavola Bianca
Torres-Mejía Gabriela
Fletcher Olivia
Allen Diane S
Allen Naomi E
Key Timothy J
Fentiman Ian S
Holly Jeff M P
Peto Julian
Article Info
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Abbr.
Cancer Epidemiol Biomarkers Prev
ISSN
1055-9965
Published
2006-03-00
Pages
449-55
Language
English
Region
United States
NLM ID
9200608
Subset
IM
Grants
Breast Cancer Now · BREAST CANCER NOW RESEARCH CENTRE · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com